Preclinical studies have shown TDO and IDO, the main rate-limiting enzymes that can regulate kynurenine pathway in patients with malignant tumors, can regulate the tryptophan-mediated tumor immune escape response through depleting tryptophan and accumulating kynurenine in the tumor microenvironment (1). The gene discussed is IDO1; the disease is cancer.